Browse the evidence

Monogenic diabetes, representing 1-4% of diabetes cases in infants and young adults, is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to inappropriate therapeutic management and worsened prognosis.

If a child or young adult is diagnosed with diabetes, ask if genetic testing for monogenic forms has been considered. Misdiagnosis as T1 or T2 can lead to incorrect treatment and worse outcomes, as monogenic diabetes often requires specific therapies different from standard insulin or oral agents.

Machine learning-guided optimization of triple agonist peptides (GCGR, GLP1R, GIPR) using Graph Attention Networks and genetic algorithms generates peptide sequences with high predicted binding affinity across all three targets, demonstrating superior computational performance over traditional Convolutional Neural Networks for GCGR prediction.

This research does not yet offer a direct treatment for patients. It describes a computational method to design better diabetes and obesity drugs. The key takeaway is that using advanced AI (Graph Attention Networks) to design peptides that target three metabolic receptors (GCGR, GLP1R, GIPR) simultaneously is more effective than older methods. This could lead to more potent drugs in the future, but no such drug is currently available for clinical use based on this paper alone.

Knockout of the lineage-specific microprotein Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation by approximately 50% in 3T3-L1 cells.

This research identifies a specific microprotein (Adipocyte-smORF-1183) in mouse fat cells that helps store fat. Knocking it out reduces fat storage by half in these cells. This is a basic science discovery about how fat cells work and does not currently translate to a human treatment or supplement.

Perioperative GLP-1 receptor agonist therapy does not significantly reduce periprosthetic joint infection or revision rates in patients undergoing total knee arthroplasty.

If you are having knee replacement, current evidence does not show that GLP-1 agonists reduce infection or revision risk. Discuss with your surgeon, but do not expect the same benefits seen in hip surgery.

1.2% of boys and men aged 15 to 35 reported use of prescription weight loss medication in the past 12 months.

Practitioners should be aware of the low prevalence of prescription weight loss medication use in this demographic.

Inhibiting miR-30e-5p using antagomirs reduces atherosclerosis in obese mouse models by restoring SLC7A11 expression and improving endothelial mitochondrial function.

While not yet a human treatment, this finding suggests that future therapies could target the specific signals fat cells send to blood vessels. For now, maintaining a healthy weight remains the most effective way to prevent these damaging signals from accumulating.

Inadvertent exposure to GLP-1 receptor agonists during pregnancy does not appear to pose a significant teratogenic risk, with congenital abnormality rates in exposed pregnancies being lower than or comparable to placebo groups.

If you took a GLP-1 medication (like Ozempic or Wegovy) before knowing you were pregnant, current data from clinical trials does not show an increased risk of birth defects compared to women who did not take these medications. You should stop the medication as soon as you know you are pregnant and consult your doctor for standard prenatal care.

There is insufficient evidence to support a causal relationship between GLP-1 receptor agonists and the risk of other common mental illnesses, including ADHD, Anorexia Nervosa, Autism Spectrum Disorder, and PTSD.

Based on this genetic study, GLP-1 drugs do not appear to reduce the risk of ADHD, Anorexia, Autism, or PTSD. Patients with these conditions should not rely on GLP-1 medications as a treatment for their mental health symptoms. Further research is needed to confirm these negative findings.

Current clinical practice for prescribing semaglutide for weight loss lacks comprehensive pretreatment screening for thyroid, pancreatic, and retinal risks, exposing patients to severe adverse outcomes.

If you are starting semaglutide for weight loss, ensure your doctor checks your calcitonin, pancreatic enzymes (lipase/amylase), and family history of thyroid cancer before starting. Standard blood tests are not enough to rule out serious risks associated with this medication.

Biomechanically calculated repair (BCR) using GRIP/CRIP concepts significantly reduces hernia recurrence rates compared to conventional repair techniques.

For complex hernias, ask if your surgeon uses biomechanical planning (GRIP/CRIP). This method tests how your abdominal wall handles daily stress before surgery, leading to a repair that is much less likely to fail (recurrence) compared to standard techniques. It may require a specialized center, but the long-term success rate is significantly higher.

Botulinum toxin A (BTA) injections and Progressive Preoperative Pneumoperitoneum (PPP) are effective mechanical optimization strategies for loss-of-domain hernias, reducing fascial tension and enabling primary closure.

If you have a very large hernia where the organs have slipped out of the abdominal cavity for a long time, standard surgery might be too risky. Your surgeon might recommend Botox injections to relax your abdominal muscles or a process called PPP (pumping air into your abdomen) to stretch your muscles before surgery. This makes it possible to close the hernia without major cutting, reducing recovery time and complications.

For individuals with obesity who fail to lose ≥2% body weight in the first 4 weeks of intensive behavioral treatment, adding phentermine (15.0 mg/day) significantly increases 24-week weight loss compared to continuing behavioral treatment with placebo.

If you have been doing intensive lifestyle changes for a month and haven't lost at least 2% of your body weight, adding phentermine (15 mg daily) to your plan can significantly boost your weight loss results compared to sticking with lifestyle changes alone. This approach helps early non-responders achieve clinically meaningful weight loss (≥5%) much more effectively. Regular monitoring of blood pressure and heart rate is recommended due to potential side effects.

High-intensity interval training (HIIT) significantly improves insulin sensitivity (fasting insulin and HOMA-IR) and cardiorespiratory fitness (VO2max) compared to moderate-intensity continuous training (MICT) in patients with diabesity.

If you have type 2 diabetes and are overweight, High-Intensity Interval Training (HIIT) may offer better improvements in insulin sensitivity and heart health than steady-state moderate exercise. HIIT involves short bursts of effort exceeding 80% of your max heart rate. It is time-efficient and can be adapted to your fitness level, making it a viable option even if you have physical limitations.

HIIT and MICT produce comparable changes in body composition, lipid profiles, fasting blood glucose, HbA1c, and blood pressure in patients with diabesity.

For weight loss, blood sugar control (HbA1c), and blood pressure, both HIIT and moderate steady-state exercise appear to work equally well for people with diabesity. You do not need to do HIIT to see improvements in these specific areas; moderate exercise is sufficient.

In patients with diabesity who have comorbidities, HIIT may significantly increase HDL cholesterol and further reduce HOMA-IR compared to MICT.

If you have type 2 diabetes, obesity, and other health conditions, HIIT might offer extra benefits for your 'good' cholesterol (HDL) and insulin resistance compared to moderate exercise. However, the evidence for this is very low certainty.

Among GLP-1 receptor agonists, Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide and Liraglutide in post-bariatric surgery patients, with the lowest rate of non-responders.

If you are using a GLP-1 agonist after bariatric surgery and not seeing enough results, ask your doctor about switching to or starting Tirzepatide. It is a newer dual-agonist that has shown greater weight loss and fewer non-responders compared to older options like Liraglutide or Semaglutide in recent studies. Note that data is currently limited to shorter-term studies.

High-intensity interval training (HIIT) significantly improves cardiometabolic health markers—including glycemic control, insulin resistance, and lipid profiles—in patients with diabesity (Type 2 Diabetes and Obesity), even when body composition changes are minimal.

If you have Type 2 Diabetes and are overweight, High-Intensity Interval Training (HIIT) is a highly effective way to improve your blood sugar and cholesterol levels, even if the scale doesn't move much. Aim for short, intense bursts of exercise (like cycling or walking) 3 times a week for about 20-30 minutes, interspersed with rest. This approach targets your metabolic health directly and is considered safe for this population when prescribed correctly.

HIIT significantly improves lipid profiles (LDL, Triglycerides, Total Cholesterol) and insulin resistance (HOMA-IR) in patients with diabesity.

Focus on improving your insulin sensitivity and cholesterol through HIIT. This type of training has been shown to significantly lower your HOMA-IR score and improve LDL and Triglyceride levels compared to doing nothing, offering a powerful metabolic boost for those with diabesity.

Protein supplementation combined with strength and conditioning training significantly increases muscular strength in athletes, whereas HMB, creatine, and vitamin D do not.

If your goal is to get stronger, ensure you are consuming enough protein alongside your strength training. This paper suggests protein is the most effective supplement for this outcome, while creatine, HMB, and vitamin D did not show significant strength benefits in this specific analysis of trained athletes.

Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks reduces medication costs by approximately 50% while maintaining 70-75% of the weight loss efficacy.

If you are on a GLP-1 medication like semaglutide or tirzepatide and cost is a major barrier, discuss with your doctor the possibility of extending your dosing interval (e.g., from once a week to once every two weeks). While you might not lose as much weight as the maximum possible, you will likely retain most of the benefit (around 75%) while cutting your medication costs in half. This is particularly useful for ensuring long-term access to the medication.

Personalized nutrition significantly reduces carbohydrate intake compared to control diets, with a median mean difference of -10.8% of energy.

Personalized nutrition interventions in this review led to a significant reduction in carbohydrate intake (averaging 10.8% less energy from carbs) compared to standard diets. This suggests that personalized approaches may naturally guide patients toward lower-carb profiles that benefit their specific metabolic health.

Personalized nutrition improves gut microbiome diversity and richness in prediabetics compared to baseline, though the effect on body weight is inconsistent and dependent on study quality.

Personalized nutrition may improve gut health (microbiome diversity) in prediabetics. However, its effect on body weight is not consistent and may depend on the quality of the study or individual response.

Concurrent long-duration static stretching (1 hour, 6 days/week) and resistance training induces significant muscle thickness hypertrophy and strength gains in highly trained bodybuilders, suggesting the modalities are complementary rather than redundant.

If you are an experienced bodybuilder looking to maximize calf growth, adding 1 hour of daily static stretching to your existing resistance training routine may yield greater muscle thickness gains than resistance training alone. Use an orthotic device to achieve high intensity (8/10 pain) during these sessions. Note that this protocol is demanding and may not be necessary or effective for untrained individuals.

Phenotype-prioritized treatment selection (SGLT2i for HF/CKD, GLP-1RA for ASCVD/Obesity) optimizes outcomes and reduces polypharmacy compared to single-disease guidelines.

Ask your doctor for a 'phenotype-first' approach. Instead of treating each condition separately, choose drugs that protect your heart, kidneys, and metabolism all at once. This can simplify your medication list and reduce side effects.